MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions
Part of paid clinical trials in Birmingham, Alabama.
- Sponsor
- Concept Medical Inc.
- Study ID
- NCT05908331
- Status
- Recruiting
Conditions
- Cardiovascular Diseases
- Coronary Artery Disease
- In-Stent Restenosis
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 110 Years
- Healthy Volunteers
- Not accepted
Interventions
- Sirolimus Drug Coated Balloon — DEVICEMagic TouchTM (Concept Medical) is a semi-compliant sirolimus drug coated balloon (SCB) for PCI, based on a polymer-free and nanocarrier based drug delivery technology.
- Plan balloon Angioplasty (POBA) — DEVICEPlan balloon used to open clogged or narrow coronary arteries due to underlying atherosclerosis
Study Details
A Prospective, Multicenter, Randomized, Two-Arm, Single-blind Superiority Trial to Evaluate the Safety and Efficacy of the MagicTouch™ Sirolimus- Coated Balloon in the Treatment of Coronary Drug-Eluting Stent In-Stent Restenosis. Subjects with prior DES implantation presenting with ISR lesions undergoing PCI will be randomized into two groups: treatment with the MagicTouch™ sirolimus-coated balloon or POBA on a 2:1 basis. Approximately 492 subjects will be enrolled in the randomized study in a maximum of 50 study sites located in the United States. The goal is to establish the safety and efficacy of the MagicTouch™ sirolimus- coated balloon in treatment of coronary in-stent restenosis (ISR).
Key Dates
- Start date
- Apr 16, 2024
- Status verified
- Feb 2025
- Primary completion
- Sep 30, 2025
- Completion
- Jul 31, 2028
Study Design
- Enrollment
- 492 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: MagicTouch Sirolimus-Coated BalloonMagic TouchTM is a Sirolimus Coated Balloon catheter intended to be used in coronary applications, treats the atherosclerosis of the coronary arteries by eluting the immunosuppressant agent Sirolimus without leaving behind a metallic scaffold.
- Active Comparator: POBAplain old balloon angioplasty
Primary Outcome Measure
TLF (Target Lesion Failure) [ Time Frame: 12 months ]
Central Contacts
- Dario Gattuso+393292467132
- Farhana Siddique+919725495366
Locations (28)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Cardiology, PC - Princeton Baptist Medical Center | Birmingham | Alabama | 35211 | - |
| Dignity Health - Mercy Gilbert Medical Center | Gilbert | Arizona | 85297 | Nabil Dib (PRINCIPAL_INVESTIGATOR) |
| Cedars - Sinai Medical Center | Los Angeles | California | 90048 | Raj Makkar (PRINCIPAL_INVESTIGATOR) |
| Yale University / Yale New Haven Hospital | New Haven | Connecticut | 06519 | - |
| Cheek-Powell Heart and Vascular Pavilion | Clearwater | Florida | 33756 | Bernardo Stein Bernardo Stein (PRINCIPAL_INVESTIGATOR) |
| Clearwater Cardiovascular and Interventional Consultants | Clearwater | Florida | 33756 | Bernardo Stein (PRINCIPAL_INVESTIGATOR) |
| The Cardiac & Vascular Institute Research Foundation | Gainesville | Florida | 32605 | Matheen Khuddus (PRINCIPAL_INVESTIGATOR) |
| Tampa General Hospital / University of South Florida | Tampa | Florida | 33606 | Hiram Bezerra (PRINCIPAL_INVESTIGATOR) |
| Atlanta VA Medical Center | Decatur | Georgia | 30033 | Rajesh Sachdeva (PRINCIPAL_INVESTIGATOR) |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | Robert Yeh (PRINCIPAL_INVESTIGATOR) |
| Metropolitan Heart and Vascular Institute | Coon Rapids | Minnesota | 55433 | Matthew G Whitbeck (PRINCIPAL_INVESTIGATOR) Randall P Stark (PRINCIPAL_INVESTIGATOR) |
| Minneapolis Heart Institute Foundation | Minneapolis | Minnesota | 55407 | Yader Sandoval (PRINCIPAL_INVESTIGATOR) |
| Cardiology Associates Research, LLC | Tupelo | Mississippi | 38801 | Barry Bertolet Barry Bertolet (PRINCIPAL_INVESTIGATOR) |
| Cardiology Associates Research, LLC | Tupelo | Mississippi | 38801 | Barry Bertolet (PRINCIPAL_INVESTIGATOR) |
| AtlantiCare Regional Medical Center | Pomona | New Jersey | 08240 | Said Ashraf (PRINCIPAL_INVESTIGATOR) |
| Columbia University Medical Center/NYPH | New York | New York | 10032 | Ajay Kirtane Jeffrey Moses (PRINCIPAL_INVESTIGATOR) |
| NYU Langone Health | New York | New York | 10016 | Natalie S. Massenburg Razzouk Louai (PRINCIPAL_INVESTIGATOR) |
| VA New York Harbor Healthcare System | New York | New York | 10010 | Nathaniel Smilowitz (PRINCIPAL_INVESTIGATOR) |
| Montefiore Medical Center - Moses Division | The Bronx | New York | 10467 | Azeem Latib Judah Rauch (PRINCIPAL_INVESTIGATOR) |
| NC Heart and Vascular Research, LLC | Raleigh | North Carolina | 27607 | James P Zidar (PRINCIPAL_INVESTIGATOR) |
| Cleveland Clinic | Cleveland | Ohio | 44195 | Amar Krishnaswamy (PRINCIPAL_INVESTIGATOR) |
| Oklahoma University Health (OU Health) | Oklahoma City | Oklahoma | 73104 | Mohit Pahuja (PRINCIPAL_INVESTIGATOR) |
| Providence St. Vincent Medical Center | Portland | Oregon | 97225 | Jason Wollmuth (PRINCIPAL_INVESTIGATOR) |
| Prisma Health | Greenville | South Carolina | 29605-5601 | Jesse Jorgensen (PRINCIPAL_INVESTIGATOR) |
| Centennial Medical Center | Nashville | Tennessee | 37203 | Brian Jefferson (PRINCIPAL_INVESTIGATOR) |
| Baylor Scott and White Heart and Vascular Hospital | Dallas | Texas | 75226 | Robert Stoler (PRINCIPAL_INVESTIGATOR) |
| Baylor Scott & White - The Heart Hospital - Plano | Plano | Texas | 75093 | Karim Al-Azizi (PRINCIPAL_INVESTIGATOR) |
| West Virginia University and Vascular Institute | Morgantown | West Virginia | 26506 | Josh Bomabrd 3042851980 Ramesh Daggubati (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Birmingham, AL
Related Studies
- TRANSCRIBE (Transcriptomic Analysis of Left Ventricular Gene Expression)Recruiting · Brigham and Women's Hospital · Boston, Massachusetts
- Evaluating Cardiovascular Phenotypes Using Induced Pluripotent Stem CellsEnrolling By Invitation · Scripps Translational Science Institute · La Jolla, California
- Product Surveillance RegistryRecruiting · Medtronic · Birmingham, Alabama
- Efficacy and Saftey Study of 99mTc-ECDG in the Evaluation of Coronary Artery Disease (CAD)PHASE2 · Not Yet Recruiting · Cell>Point LLC · Oklahoma City, Oklahoma